U.K. drugmaker GlaxoSmithKline (GSK) has admitted that it found bribery problems with its China vaccine business in 2001 that led to the firing of about 30 employees, according to a Thursday story in the Financial Times.
The incident puts the British company under heightened scrutiny as China, the U.K. and the U.S. are all investigating allegations that GSK has recently paid up to $500 million in bribes to doctors and hospitals to boost its drug sales in China.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
